Datroway Continues To Show Promising Tumor Responses As Part Of Combination Regimens In Patients With Early And Advanced Non-Small Cell Lung Cancer
June 1 (Reuters) - Daiichi Sankyo Co Ltd 4568.T:
DATROWAY® CONTINUES TO SHOW PROMISING TUMOR RESPONSES AS PART OF COMBINATION REGIMENS IN PATIENTS WITH EARLY AND ADVANCED NON-SMALL CELL LUNG CANCER
DAIICHI SANKYO CO LTD - PHASE 2 RESULTS SHOW POTENTIAL FOR DATROWAY PLUS DURVALUMAB
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.